Crystec launch a new R&D centre in Haimen, Jiangsu province, China
HAIMEN, CHINA: March 31, 2021
Crystec are pleased to announce the opening of a new subsidiary, Nantong Crystec Pharmaceutical R&D Co. Ltd., and research facility, located at Haimen Science and Technology Park in Haimen City, Jiangsu Province, China.
Crystec’s new R&D centre has been established following an invitation to participate in the Yangtze Delta Advanced Drug Development platform jointly funded by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the Haimen government. The platform, which has received £550m equivalent in investment, is dedicated to accelerating pharmaceutical product innovation underpinned by advanced pharmaceutical excipients and drug delivery technologies. Crystec’s mSAS® technology will play a key role in enabling the development of new therapeutics, creation of value added medicines, and in simplification of formulations and manufacturing processes.
Dr. Qun Shao, Crystec’s Chief Operations Officer said:
“We are delighted to open our new facility in Haimen, a project credited to the collaborative efforts of SIMM, Chinese Academy of Sciences and the Haimen government. This cutting-edge research facility will enhance our capacity to support clients across China and the rest of the world, and will provide opportunities to achieve rapid transition from proof of concept studies to delivering clinical material for human trials in China”.
The new Haimen facility will support Crystec’s ongoing development strategy in China, working alongside Crystec’s existing China subsidiary, Tianjin Crystec Pharmaceutical Technology Ltd., and its UK headquarters in Bradford, UK, to expand and enhance product development services offered across the region and globally.
For further information, please contact Emily Bevis, Business Development Manager
emily.bevis@crystecpharma.com, +44 1274 235592
About CrystecPharma
CrystecPharma is a pharmaceutical crystal and particle engineering company, applying proprietary mSAS® supercritical fluid technology to improve the performance of medicines. The company has a strong research and development base, in both the UK and China. Crystec supports pharmaceutical companies to optimise the development of their own products, typically through improving bioavailability, stability or changing routes of administration. Use of the mSAS® platform can greatly shorten development times, generating high quality, readily-scalable products. The company also applies the strength of its technology to develop its own unique supergeneric products. Crystec is a young, dynamic company, with a passion for ensuring that strong science benefits human health.
For more information, please visit www.crystecpharma.com.
To keep up to date with the latest news from Crystec, please follow us on LinkedIn.